Three years after a spinoff from Takeda, Phathom Pharmaceuticals has successfully crossed the FDA finish line with a drug it got from the Japanese pharma.
The FDA cleared Phathom’s vonoprazan in two combinations to treat Helicobacter pylori infection, which typically affects the stomach or the small intestine, the company said Tuesday. Takeda has been selling the therapy in several Asian markets.